Carla della Ventura

Dr. Carla della Ventura


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
CGCristina Galli
Cristina Galli
EEErika Ebranati
Erika Ebranati
LPLaura Pellegrinelli
Laura Pellegrinelli
MAMartina Airoldi
Martina Airoldi
CVCarla Veo
Carla Veo
EPElena Pariani
Elena Pariani
(1) Background: Over the last few years, there has been growing interest in the whole genome sequencing (WGS) of rapidly mutating pathogens, such as influenza viruses (IVs), which has led us to carry out in-depth studies on viral evolution in both research and diagnostic settings. We aimed at describing and determining the validity of a WGS protocol that can obtain the complete genome sequence of A(H3N2) IVs directly from clinical specimens. (2) Methods: RNA was extracted from 80 A(H3N2)-positive respiratory specimens. A one-step RT-PCR assay, based on the use of a single set of specific primers, was used to retro-transcribe and amplify the entire IV type A genome in a single reaction, thus avoiding additional enrichment approaches and host genome removal treatments. Purified DNA was quantified; genomic libraries were prepared and sequenced by using Illumina MiSeq platform. The obtained reads were evaluated for sequence quality and read-pair length. (3) Results: All of the study specimens were successfully amplified, and the purified DNA concentration proved to be suitable for NGS (at least 0.2 ng/µL). An acceptable coverage depth for all eight genes of influenza A(H3N2) virus was obtained for 90% (72/80) of the clinical samples with viral loads >105 genome copies/mL. The mean depth of sequencing ranged from 105 to 200 reads per position, with the majority of the mean depth values being above 103 reads per position. The total turnaround time per set of 20 samples was four working days, including sequence analysis. (4) Conclusions: This fast and reliable high-throughput sequencing protocol should be used for influenza surveillance and outbreak investigation.

12 November 2022 in Viruses
Verified
Journal Article
Open access
PDF file
ALAlessia Lai
Alessia Lai
ABAnnalisa Bergna
Annalisa Bergna
CVCarla della Ventura
Carla della Ventura
Stefano MenzoStefano Menzo
Stefano Menzo
BBBianca Bruzzone
Bianca Bruzzone
SGSARS-CoV- ITALIAN RESEARCH ENTERPRISE–(SCIRE) Collaborative Group
SARS-CoV- ITALIAN RESEARCH ENTERPRISE–(SCIRE) Collaborative Group
SARS-CoV-2 is constantly evolving, leading to new variants. We analysed data from 4400 SARS-CoV-2-positive samples in order to pursue epidemiological variant surveillance and to evaluate their impact on public health in Italy in the period of April–December 2021. The main circulating strain (76.2%) was the Delta variant, followed by the Alpha (13.3%), the Omicron (5.3%), and the Gamma variants (2.9%). The B.1.1 lineages, Eta, Beta, Iota, Mu, and Kappa variants, represented around 1% of cases. There were 48.2% of subjects who had not been vaccinated, and they had a lower median age compared to the vaccinated subjects (47 vs. 61 years). An increasing number of infections in the vaccinated subjects were observed over time, with the highest proportion in November (85.2%). The variants correlated with clinical status; the largest proportion of symptomatic patients (59.6%) was observed with the Delta variant, while subjects harbouring the Gamma variant showed the highest proportion of asymptomatic infection (21.6%), albeit also deaths (5.4%). The Omicron variant was only found in the vaccinated subjects, of which 47% had been hospitalised. The diffusivity and pathogenicity associated with the different SARS-CoV-2 variants are likely to have relevant public health implications, both at the national and international levels. Our study provides data on the rapid changes in the epidemiological landscape of the SARS-CoV-2 variants in Italy.

16 September 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
ALAlessia Lai
Alessia Lai
ABAnnalisa Bergna
Annalisa Bergna
CVCarla della Ventura
Carla della Ventura
Stefano MenzoStefano Menzo
Stefano Menzo
BBBianca Bruzzone
Bianca Bruzzone
Gianguglielmo ZehenderGianguglielmo Zehender
Gianguglielmo Zehender
SARS-CoV-2 is constantly evolving leading to new variants. We analysed data from 4,400 SARS-CoV-2-positive samples in order to continue variant surveillance in Italy to evaluate their epidemiological and relative impact on public health in the period April-December 2021. The main circulating strain (76.2%) was Delta followed by Alpha (13.3%), Omicron (5.3%) and Gamma variants (2.9%). B.1.1 lineages, Eta, Beta, Iota, Mu and Kappa variants represented around 1% of cases. Overall, 48.2% of subjects were not vaccinated with a lower median age compared to vaccinated subjects (47 vs. 61 years). An increasing number of infections in vaccinated subjects was observed overtime, with the highest proportion in November (85.2%). Variants correlated with clinical status; the largest proportion of symptomatic patients (59.6%) was observed among Delta variant, while subjects harboring Gamma variant showed the highest proportion of asymptomatics (21.6%), albeit also of deaths (5.4%). The Omicron variant was only found in vac-cinated subjects, of which 47% were hospitalized. Diffusivity and pathogenicity associated with the different SARS-CoV-2 variants are likely to have relevant public health implications, both at national and international level. Our study pro-vides data on the rapid changes in the epidemiological landscape of SARS-CoV-2 variants in Italy.

13 November 2025 in Journal of General Virology
Verified
Journal Article
Open access
Marta GiovanettiMarta Giovanetti
Marta Giovanetti
Eleonora CellaEleonora Cella
Eleonora Cella
LSLaura Soliani
Laura Soliani
APAlice Prosperi
Alice Prosperi
AMAda Mescoli
Ada Mescoli
Ana MorenoAna Moreno
Ana Moreno
The influenza A H1N1pdm09 virus continues to pose a significant zoonotic threat, with implications for both animal and human health. Italy, which hosts one of the largest swine populations in Europe, is strategically positioned to monitor the evolution of influenza viruses in livestock. This study addresses the genetic diversity and transmission dynamics of H1N1pdm09 in Italian swine, using whole-genome sequencing and dynamic modelling of samples collected from farms across the country. Our findings indicate multiple independent introductions of H1N1pdm09 into Italy. While most were self-limiting, six distinct transmission clusters suggest localized and sustained spread across various regions. Although many introductions were contained, certain lineages demonstrated the ability to circulate within specific areas. Selective pressure analyses showed strong purifying selection across most viral genes in both swine and human hosts, with non-synonymous to synonymous substitution rate (dN/dS) ratios well below 1. The haemagglutinin gene exhibited a higher dN/dS ratio in swine (~0.28) than in humans (~0.22), indicating slightly relaxed selection in swine. Neuraminidase and non-structural proteins were similarly constrained in both hosts. This study underscores the importance of ongoing genomic surveillance to detect viral circulation and mitigate zoonotic risks. Italy’s contribution supports global influenza monitoring and reinforces the need for a One Health approach that integrates human, animal and environmental health. These insights are crucial for informing public health strategies and improving preparedness for future outbreaks.

24 December 2025 in One Health
Verified
Journal Article
Open access
CVCarla della Ventura
Carla della Ventura
MCMaya Carrera
Maya Carrera
FDfrancesco defilippo
francesco defilippo
Davide LelliDavide Lelli
Davide Lelli
CNChiara Nogarol
Chiara Nogarol
Gianguglielmo ZehenderGianguglielmo Zehender
Gianguglielmo Zehender
Since its introduction to Europe in 2004, West Nile Virus Lineage 2 (WNV-2) has become endemic, with Italy reporting the highest number of cases each season. In 2022, WNV infections in Italy exceeded those recorded during the major 2018 outbreak—the largest ever reported in Europe. This study investigates the genomic epidemiology of WNV during the 2022 and 2023 transmission seasons.